Cargando…
A new monoclonal antibody that blocks dimerisation and inhibits c-kit mutation-driven tumour growth
PURPOSE: Imatinib, a small-molecule tyrosine kinase inhibitor, has shown good clinical activity by inhibiting adenosine triphosphate (ATP) binding to the receptor. Unfortunately, majority of patients eventually develop drug resistance, which limits the long-term benefits of the tyrosine kinase inhib...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954730/ https://www.ncbi.nlm.nih.gov/pubmed/33389076 http://dx.doi.org/10.1007/s00432-020-03490-6 |